{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.17","value":"0.7"},{"groupId":"OG001","spread":"7.05","value":"0.1"},{"groupId":"OG002","spread":"5.92","value":"1.9"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"1.0"},{"groupId":"OG004","spread":"6.52","value":"-4.0"},{"groupId":"OG005","spread":"11.08","value":"-1.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Change from baseline Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.14","value":"-1.7"},{"groupId":"OG001","spread":"4.56","value":"-2.7"},{"groupId":"OG002","spread":"7.24","value":"1.3"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"-4.0"},{"groupId":"OG004","spread":"8.10","value":"-6.5"},{"groupId":"OG005","spread":"9.08","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Change from baseline Day 29"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.42","value":"-2.8"},{"groupId":"OG001","spread":"4.20","value":"-2.0"},{"groupId":"OG002","spread":"9.99","value":"-3.3"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"-4.0"},{"groupId":"OG004","spread":"8.33","value":"-4.7"},{"groupId":"OG005","spread":"9.95","value":"-0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Change from baseline Day 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.42","value":"-0.4"},{"groupId":"OG001","spread":"3.83","value":"-2.8"},{"groupId":"OG002","spread":"9.25","value":"0.6"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"-5.0"},{"groupId":"OG004","spread":"8.50","value":"-6.7"},{"groupId":"OG005","spread":"8.67","value":"-1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"title":"Change from baseline Day 90"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.14","value":"0.6"},{"groupId":"OG001","spread":"5.65","value":"-1.8"},{"groupId":"OG002","spread":"10.20","value":"-3.6"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"2.0"},{"groupId":"OG004","spread":"7.00","value":"-8.0"},{"groupId":"OG005","spread":"7.27","value":"1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Change from baseline Day 180"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.78","value":"-0.3"},{"groupId":"OG001","spread":"2.25","value":"-3.7"},{"groupId":"OG002","spread":"10.07","value":"-1.0"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"-8.0"},{"groupId":"OG004","spread":"12.53","value":"-10.00"},{"groupId":"OG005","spread":"5.22","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Change from baseline Day 270"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.01","value":"1.3"},{"groupId":"OG001","spread":"3.30","value":"-3.3"},{"groupId":"OG002","spread":"12.03","value":"2.0"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"-6.0"},{"groupId":"OG004","spread":"10.69","value":"-6.7"},{"groupId":"OG005","spread":"7.33","value":"1.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Change from baseline Day 365"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.14","value":"0.7"},{"groupId":"OG001","spread":"4.35","value":"-3.7"},{"groupId":"OG002","spread":"4.16","value":"-4.7"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"-3.0"},{"groupId":"OG004","spread":"6.36","value":"3.5"},{"groupId":"OG005","spread":"4.85","value":"-1.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}],"units":"Participants"}],"title":"Change from baseline Day 545"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.12","value":"1.4"},{"groupId":"OG001","spread":"1.33","value":"-0.8"},{"groupId":"OG002","spread":"5.32","value":"-1.8"},{"comment":"Insufficient number of participants to calculate standard deviation.","groupId":"OG003","spread":"NA","value":"-2.0"},{"groupId":"OG004","spread":"12.02","value":"-1.5"},{"groupId":"OG005","spread":"1.29","value":"-1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"title":"Change from baseline Day 730"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"9"}],"units":"Participants"}],"description":"The Functional Assessment of Cancer Treatment-Lymphoma \"Additional concerns\" subscale (FACT-LymS) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. Only the LYM subscale was administered in this study. The LYM items are scored on a 0 (\"Not at all\") to 4 (\"Very much\") response scale. Items are aggregated to a single score on a 0-60 scale. Lower scores indicate better health outcomes. Baseline the last available recorded scores on or prior to the date of JCAR017 infusion.","dispersionType":"Standard Deviation","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG001","title":"Cohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG002","title":"Cohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 2"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG003","title":"Cohort 4: Newly Diagnosed High-Grade B-cell Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG004","title":"Cohort 5: Primary Central Nervous System Lymphoma"},{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG005","title":"Cohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting"}],"paramType":"MEAN","populationDescription":"All participants in the JCAR017-treated set with completed baseline questionnaires and with at least one completed post-baseline questionnaire.","reportingStatus":"POSTED","timeFrame":"At baseline and Day 1, 29, 60, 90, 180, 270, 365, 545, and 730 post JCAR017 infusion.","title":"Change From Baseline in Functional Assessment of Cancer Treatment-Lymphoma \"Additional Concerns\" Subscale (FACT-LymS) Scores","type":"SECONDARY","unitOfMeasure":"Scores on a Scale"}